XBiotech Inc. (XBIT) Stake Lessened by Schwab Charles Investment Management Inc.

Schwab Charles Investment Management Inc. reduced its position in shares of XBiotech Inc. (NASDAQ:XBIT) by 41.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 37,383 shares of the biopharmaceutical company’s stock after selling 26,820 shares during the period. Schwab Charles Investment Management Inc. owned about 0.11% of XBiotech worth $176,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in XBIT. Vanguard Group Inc. lifted its position in shares of XBiotech by 4.8% during the 1st quarter. Vanguard Group Inc. now owns 744,176 shares of the biopharmaceutical company’s stock worth $12,272,000 after purchasing an additional 33,899 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of XBiotech by 32.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 98,799 shares of the biopharmaceutical company’s stock worth $1,629,000 after purchasing an additional 24,434 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of XBiotech by 670.5% during the 1st quarter. JPMorgan Chase & Co. now owns 24,840 shares of the biopharmaceutical company’s stock worth $410,000 after purchasing an additional 21,616 shares during the last quarter. KCG Holdings Inc. purchased a new stake in shares of XBiotech during the 1st quarter worth $186,000. Finally, Geode Capital Management LLC lifted its position in shares of XBiotech by 4.9% during the 1st quarter. Geode Capital Management LLC now owns 152,318 shares of the biopharmaceutical company’s stock worth $2,511,000 after purchasing an additional 7,066 shares during the last quarter. 10.68% of the stock is owned by institutional investors and hedge funds.

Shares of XBiotech Inc. (NASDAQ:XBIT) opened at $3.97 on Tuesday. XBiotech Inc. has a 1 year low of $2.77 and a 1 year high of $20.18.

COPYRIGHT VIOLATION WARNING: This story was first published by Markets Daily and is the property of of Markets Daily. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.themarketsdaily.com/2017/11/14/xbiotech-inc-xbit-stake-lessened-by-schwab-charles-investment-management-inc.html.

XBiotech Profile

XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response.

Want to see what other hedge funds are holding XBIT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for XBiotech Inc. (NASDAQ:XBIT).

Institutional Ownership by Quarter for XBiotech (NASDAQ:XBIT)

Receive News & Ratings for XBiotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply